EV-based Neurorestorative Therapy
Neurological injury in newborn infants
Pre-clinicalActive
Key Facts
Indication
Neurological injury in newborn infants
Phase
Pre-clinical
Status
Active
Company
About Exosla Therapeutics
Exosla Therapeutics is a private, pre-clinical stage biotech developing a novel extracellular vesicle (EV)-based immunotherapy platform. The company's technology aims to overcome historical challenges in EV manufacturing, such as batch-to-batch variability, by using EVs from specific, immortalized monoclonal MSC lines to create a standardized, scalable product. With a seasoned leadership team combining deep EV science, clinical neurology, and biopharma entrepreneurship, Exosla is positioned to advance its lead program towards clinical trials for neonatal neurological conditions while exploring broader applications in restorative medicine.
View full company profile